MINK THERAPEUTICS AND UNIVERSITY OF WISCONSIN–MADISON ANNOUNCE PHASE 1 CLINICAL TRIAL OF ALLO-INKT CELL THERAPY (AGENT-797) TO EVALUATE PREVENTION OF GRAFT-VERSUS-HOST DISEASE

Reuters · 4d ago

Please log in to view news